Akari Therapeutics (AKTX) Competitors $1.16 -0.01 (-0.86%) Closing price 03:59 PM EasternExtended Trading$1.16 +0.00 (+0.43%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLFShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Lyell Immunopharma BeyondSpring Neumora Therapeutics Nkarta FitLife Brands Akari Therapeutics (NASDAQ:AKTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Is AKTX or FATE more profitable? Akari Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A -213.59% -65.60% Fate Therapeutics -1,318.93%-47.17%-34.60% Which has more volatility and risk, AKTX or FATE? Akari Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Does the media refer more to AKTX or FATE? In the previous week, Akari Therapeutics and Akari Therapeutics both had 2 articles in the media. Akari Therapeutics' average media sentiment score of 0.82 beat Fate Therapeutics' score of 0.65 indicating that Akari Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, AKTX or FATE? Akari Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$19.79MN/AN/AFate Therapeutics$13.63M9.42-$186.26M-$1.49-0.75 Do institutionals and insiders believe in AKTX or FATE? 5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 38.1% of Akari Therapeutics shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer AKTX or FATE? Fate Therapeutics has a consensus price target of $3.83, indicating a potential upside of 242.26%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 SummaryFate Therapeutics beats Akari Therapeutics on 8 of the 12 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.17M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.13%P/E RatioN/A21.3126.2119.90Price / SalesN/A241.40405.84161.31Price / CashN/A41.8936.4957.06Price / Book1.387.518.055.38Net Income-$19.79M-$55.05M$3.15B$248.50M7 Day Performance-0.43%2.45%1.85%2.97%1 Month Performance-18.37%7.33%4.81%6.02%1 Year Performance-62.74%5.38%34.86%20.39% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics1.609 of 5 stars$1.16-0.9%N/A-64.2%$37.17MN/A0.009News CoverageFATEFate Therapeutics4.0881 of 5 stars$1.14-4.2%$3.83+236.3%-65.0%$136.38M$13.63M-0.77550Gap DownKYTXKyverna Therapeutics1.5918 of 5 stars$3.22+4.9%$18.50+474.5%-64.5%$132.68M$7.03M-0.9596BDTXBlack Diamond Therapeutics3.2599 of 5 stars$2.27-2.6%$14.60+543.2%-47.2%$132.49MN/A37.8390Positive NewsAnalyst UpgradeVXRTVaxart2.3402 of 5 stars$0.56-3.4%$3.00+435.3%-33.2%$132.42M$28.70M-2.08120Positive NewsGap DownLXEOLexeo Therapeutics2.4959 of 5 stars$3.96+1.3%$16.60+319.2%-73.0%$129.80M$650K-1.2058News CoverageLYELLyell Immunopharma3.3142 of 5 stars$8.99+3.5%$20.00+122.5%-70.2%$128.68M$60K-0.36270BYSIBeyondSpringN/A$2.74-13.6%N/A-2.0%$127.80M$1.75M0.0080High Trading VolumeNMRANeumora Therapeutics2.5663 of 5 stars$0.75-5.1%$9.29+1,144.7%-92.0%$127.08MN/A-0.46108News CoveragePositive NewsNKTXNkarta2.2473 of 5 stars$1.75-1.4%$14.33+721.4%-70.8%$125.60MN/A-1.16140News CoverageFTLFFitLife Brands4.3806 of 5 stars$12.99-2.5%$20.50+57.8%-14.3%$125.09M$64.47M15.4620 Related Companies and Tools Related Companies Fate Therapeutics Competitors Kyverna Therapeutics Competitors Black Diamond Therapeutics Competitors Vaxart Competitors Lexeo Therapeutics Competitors Lyell Immunopharma Competitors BeyondSpring Competitors Neumora Therapeutics Competitors Nkarta Competitors FitLife Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
